Sep. 13 at 10:02 PM
$LXRX Pilavapadin is currently being tested for DPNP, a sizeable market but a subset of one of the biggest pharmaceutical markets:
"The non-opioid pain management market has significant growth potential, expected to reach between
$70 billion and
$91 billion by 2030-2034, with a compound annual growth rate (CAGR) of 7.7% to 8.1%. This expansion is driven by the global opioid crisis, leading to increased demand for safer alternatives, supported by rising R&D, government initiatives, technological advancements in devices and formulations, and the growing elderly population experiencing chronic pain."
There're many ways that this could be played out. One of those is multi-
$B's partnership deal, and the other is to sell it outright, which I believe should be worth between
$5B (
$15/sh) to
$8B (
$24/sh) or more. Then we still have Inpefa (HF, HCM, MI, stroke), LX9851 and a handful of drug candidate from gene-knockout animal trials plus T1DM.
